-DOCSTART- -X- O
Newcastle -X- _ B-Intervention
disease -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
NDV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
an -X- _ O
avian -X- _ O
virus -X- _ O
, -X- _ O
is -X- _ O
being -X- _ O
evaluated -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
vectored -X- _ O
human -X- _ O
vaccines -X- _ O
against -X- _ O
emerging -X- _ O
pathogens. -X- _ O
Previous -X- _ O
studies -X- _ O
of -X- _ O
NDV-vectored -X- _ B-Intervention
vaccines -X- _ I-Intervention
in -X- _ O
a -X- _ O
mouse -X- _ O
model -X- _ O
suggested -X- _ O
their -X- _ O
potency -X- _ O
after -X- _ O
delivery -X- _ O
by -X- _ O
injection -X- _ B-Intervention
or -X- _ I-Intervention
by -X- _ I-Intervention
the -X- _ I-Intervention
intranasal -X- _ I-Intervention
route. -X- _ I-Intervention
We -X- _ O
compared -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
various -X- _ O
routes -X- _ O
of -X- _ O
delivery -X- _ O
of -X- _ O
NDV-vectored -X- _ B-Intervention
vaccines -X- _ I-Intervention
in -X- _ O
a -X- _ O
non-human -X- _ B-Patient
primate -X- _ I-Patient
model. -X- _ I-Patient
While -X- _ O
delivery -X- _ O
of -X- _ O
an -X- _ O
NDV -X- _ B-Outcome
vectored -X- _ I-Outcome
vaccine -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
combined -X- _ I-Outcome
intranasal -X- _ I-Outcome
/ -X- _ I-Outcome
intratracheal -X- _ I-Outcome
route -X- _ I-Outcome
elicited -X- _ I-Outcome
protective -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
delivery -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
subcutaneous -X- _ I-Outcome
route -X- _ I-Outcome
or -X- _ I-Outcome
the -X- _ I-Outcome
intranasal -X- _ I-Outcome
route -X- _ I-Outcome
alone -X- _ I-Outcome
elicited -X- _ I-Outcome
limited -X- _ I-Outcome
or -X- _ I-Outcome
no -X- _ I-Outcome
protective -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ O
suggesting -X- _ O
the -X- _ O
necessity -X- _ O
for -X- _ O
vaccine -X- _ O
delivery -X- _ O
to -X- _ O
the -X- _ O
lower -X- _ O
respiratory -X- _ O
tract. -X- _ O
Furthermore -X- _ O
, -X- _ O
direct -X- _ O
comparison -X- _ O
of -X- _ O
a -X- _ O
vaccine -X- _ O
based -X- _ O
on -X- _ O
an -X- _ O
NDV -X- _ O
mesogenic -X- _ O
strain -X- _ O
( -X- _ O
NDV-BC -X- _ O
) -X- _ O
with -X- _ O
a -X- _ O
similarly -X- _ O
designed -X- _ O
NDV -X- _ O
vector -X- _ O
based -X- _ O
on -X- _ O
a -X- _ O
modified -X- _ O
lentogenic -X- _ O
strain -X- _ O
carrying -X- _ O
a -X- _ O
polybasic -X- _ O
F -X- _ O
cleavage -X- _ O
site -X- _ O
( -X- _ O
NDV-VF -X- _ O
) -X- _ O
suggested -X- _ O
that -X- _ O
the -X- _ O
two -X- _ O
NDV -X- _ O
strains -X- _ O
were -X- _ O
similar -X- _ O
in -X- _ O
immunogenicity -X- _ O
and -X- _ O
were -X- _ O
equally -X- _ O
protective -X- _ O
. -X- _ O

